These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32933995)

  • 41. Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.
    Mota JM; Teo MY; Whiting K; Li HA; Regazzi AM; Lee CH; Funt SA; Bajorin D; Ostrovnaya I; Iyer G; Rosenberg JE
    J Immunother; 2021 Sep; 44(7):248-253. PubMed ID: 34081050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
    Fukuokaya W; Kimura T; Komura K; Uchimoto T; Nishimura K; Yanagisawa T; Imai Y; Iwatani K; Ito K; Urabe F; Tsuzuki S; Kimura S; Terada N; Mukai S; Oyama Y; Abe H; Kamoto T; Azuma H; Miki J; Egawa S
    Urol Oncol; 2022 Jul; 40(7):346.e1-346.e8. PubMed ID: 35346571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
    Kano H; Ichihara E; Harada D; Inoue K; Kayatani H; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Ninomiya K; Hotta K; Maeda Y; Kiura K
    Cancer Sci; 2020 Oct; 111(10):3739-3746. PubMed ID: 32726470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
    Deng R; Zhang H; Li Y; Shi Y
    J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials.
    Robesti D; Nocera L; Belladelli F; Schultz JG; Fallara G; Marandino L; Raggi D; Montorsi F; Msaouel P; Necchi A; Martini A
    BJU Int; 2024 Feb; 133(2):158-168. PubMed ID: 37422731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
    Takada K; Shimokawa M; Takamori S; Shimamatsu S; Hirai F; Ono Y; Tagawa T; Okamoto T; Hamatake M; Okamoto I; Mori M
    PLoS One; 2022; 17(2):e0263247. PubMed ID: 35130287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
    Horvath A; Rainer F; Bashir M; Leber B; Schmerboeck B; Klymiuk I; Groselj-Strele A; Durdevic M; Freedberg DE; Abrams JA; Fickert P; Stiegler P; Stadlbauer V
    Sci Rep; 2019 Aug; 9(1):12000. PubMed ID: 31427714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
    Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
    J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
    [No Abstract]   [Full Text] [Related]  

  • 51. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
    Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
    Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
    Front Immunol; 2021; 12():666909. PubMed ID: 34149702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma.
    Economopoulou P; Kotsantis I; Bamias A
    Expert Opin Drug Saf; 2020 Aug; 19(8):955-960. PubMed ID: 32657630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice.
    Takashima S; Tanaka F; Kawaguchi Y; Usui Y; Fujimoto K; Nadatani Y; Otani K; Hosomi S; Nagami Y; Kamata N; Taira K; Tanigawa T; Watanabe T; Imoto S; Uematsu S; Fujiwara Y
    Neurogastroenterol Motil; 2020 Jul; 32(7):e13841. PubMed ID: 32319196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy.
    Kichenadasse G; Miners JO; Mangoni AA; Karapetis CS; Hopkins AM; Sorich MJ
    J Natl Compr Canc Netw; 2021 May; 19(9):1037-1044. PubMed ID: 33951613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.
    Abuhelwa AY; Bellmunt J; Kichenadasse G; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
    Clin Genitourin Cancer; 2022 Apr; 20(2):132-138. PubMed ID: 34953754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
    Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
    Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
    Kim SY; Lee JS; Kang J; Morita S; Park YS; Sakamoto J; Muro K; Xu RH; Kim TW
    Oncologist; 2021 Jun; 26(6):e954-e962. PubMed ID: 33644953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.